Pharmakure's key focus is Alzheimer's Disease, where no effective treatments exist, leading to enormous human and financial cost

Our strategy is to discover new uses for known compounds or drugs through our phenotypic screening methods

This strategy offers great promise for quickly bringing new therapeutic options to Alzheimer's patients

PharmaKure already owns intellectual property on one
drug discovered by our screening approach

This first drug PK051 is ready for Phase 2 clinical trials

IF WE COULD DELAY THE AGE OF ONSET OF ALZHEIMER'S DISEASE BY 5 YEARS

THERE WOULD BE ENORMOUS HUMAN AND FINANCIAL BENEFITS

PharmaKure is a drug development company

a spin out from The University of Manchester